Biopsy-proven Histologic Scores clinical trials at University of California Health

1 in progress, 0 open to eligible people

ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Sorry, not yet accepting patients
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
at UCLA

Last updated: January 24, 2025